Crow, Mary K

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology

Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related Diseases

Cited by 2,677

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Annals of the Rheumatic Diseases

Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related Diseases

Cited by 1,612

Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology

Immune Response and InflammationAdvanced Glycation End Products research

Cited by 1,372

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 746

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis

Pearle, A. D., Scanzello, C. R., George, S., Mandl, L. A., DiCarlo, E. F., Peterson, M., Sculco, T. P., & Crow, M. K. (2007) · Osteoarthritis and Cartilage

Osteoarthritis Treatment and MechanismsRheumatoid Arthritis Research and Therapies

Cited by 362

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 173

Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes

Mavragani, C. P., Nezos, A., Sagalovskiy, I., Seshan, S., Kirou, K. A., & Crow, M. K. (2018) · Journal of Autoimmunity

Salivary Gland Disorders and FunctionsEpigenetics and DNA Methylation

Cited by 85

European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

Aringer, M., Brinks, R., Dörner, T., Daikh, D., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2021) · Annals of the Rheumatic Diseases

Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related Diseases

Cited by 68